User login
Key clinical point: Over 68-week continuous treatment, 4 mg and 2 mg baricitinib plus topical corticosteroids (TCS) showed clinically meaningful efficacy in patients with moderate-to-severe atopic dermatitis (AD).
Major finding: The proportions of patients with a validated Investigator’s Global Assessment for AD score of 0/1 at weeks 32/68 in the 4 mg baricitinib intent-to-treat, 4 mg baricitinib responder or partial responder (RPR), and 2 mg baricitinib RPR cohorts were 21.6%/23.5%, 31.7%/34.9%, and 45.3%/30.2%, respectively; Eczema Area and Severity Index 75 response rates were 46.1%/43.1%, 57.1%/49.2%, and 69.8%/58.5%, respectively.
Study details: This ongoing extension study of BREEZE-AD7 (BREEZE-AD3) included 292 patients with moderate-to-severe AD, of which RPR receiving 2 mg baricitinib +TCS/4 mg baricitinib + TCS continued their original treatment, nonresponders receiving 2 mg baricitinib were reassigned to receive 2 mg or 4 mg baricitinib, and nonresponders receiving 4 mg baricitinib continued their treatment.
Disclosures: This study was funded by Eli Lilly and Company, under license from Incyte Corporation. Some authors reported ties with various organizations, including Eli Lilly. Four authors declared being employees and stockholders of Eli Lilly.
Source: Silverberg JI et al. Long-term efficacy (up to 68 weeks) of baricitinib in combination with topical corticosteroids in adult patients with moderate-to-severe atopic dermatitis: Analysis of treatment responders, partial responders and nonresponders originating from study BREEZE-AD7. J Eur Acad Dermatol Venereol. 2023 (Dec 14, 2022). Doi: 10.1111/jdv.18816
Key clinical point: Over 68-week continuous treatment, 4 mg and 2 mg baricitinib plus topical corticosteroids (TCS) showed clinically meaningful efficacy in patients with moderate-to-severe atopic dermatitis (AD).
Major finding: The proportions of patients with a validated Investigator’s Global Assessment for AD score of 0/1 at weeks 32/68 in the 4 mg baricitinib intent-to-treat, 4 mg baricitinib responder or partial responder (RPR), and 2 mg baricitinib RPR cohorts were 21.6%/23.5%, 31.7%/34.9%, and 45.3%/30.2%, respectively; Eczema Area and Severity Index 75 response rates were 46.1%/43.1%, 57.1%/49.2%, and 69.8%/58.5%, respectively.
Study details: This ongoing extension study of BREEZE-AD7 (BREEZE-AD3) included 292 patients with moderate-to-severe AD, of which RPR receiving 2 mg baricitinib +TCS/4 mg baricitinib + TCS continued their original treatment, nonresponders receiving 2 mg baricitinib were reassigned to receive 2 mg or 4 mg baricitinib, and nonresponders receiving 4 mg baricitinib continued their treatment.
Disclosures: This study was funded by Eli Lilly and Company, under license from Incyte Corporation. Some authors reported ties with various organizations, including Eli Lilly. Four authors declared being employees and stockholders of Eli Lilly.
Source: Silverberg JI et al. Long-term efficacy (up to 68 weeks) of baricitinib in combination with topical corticosteroids in adult patients with moderate-to-severe atopic dermatitis: Analysis of treatment responders, partial responders and nonresponders originating from study BREEZE-AD7. J Eur Acad Dermatol Venereol. 2023 (Dec 14, 2022). Doi: 10.1111/jdv.18816
Key clinical point: Over 68-week continuous treatment, 4 mg and 2 mg baricitinib plus topical corticosteroids (TCS) showed clinically meaningful efficacy in patients with moderate-to-severe atopic dermatitis (AD).
Major finding: The proportions of patients with a validated Investigator’s Global Assessment for AD score of 0/1 at weeks 32/68 in the 4 mg baricitinib intent-to-treat, 4 mg baricitinib responder or partial responder (RPR), and 2 mg baricitinib RPR cohorts were 21.6%/23.5%, 31.7%/34.9%, and 45.3%/30.2%, respectively; Eczema Area and Severity Index 75 response rates were 46.1%/43.1%, 57.1%/49.2%, and 69.8%/58.5%, respectively.
Study details: This ongoing extension study of BREEZE-AD7 (BREEZE-AD3) included 292 patients with moderate-to-severe AD, of which RPR receiving 2 mg baricitinib +TCS/4 mg baricitinib + TCS continued their original treatment, nonresponders receiving 2 mg baricitinib were reassigned to receive 2 mg or 4 mg baricitinib, and nonresponders receiving 4 mg baricitinib continued their treatment.
Disclosures: This study was funded by Eli Lilly and Company, under license from Incyte Corporation. Some authors reported ties with various organizations, including Eli Lilly. Four authors declared being employees and stockholders of Eli Lilly.
Source: Silverberg JI et al. Long-term efficacy (up to 68 weeks) of baricitinib in combination with topical corticosteroids in adult patients with moderate-to-severe atopic dermatitis: Analysis of treatment responders, partial responders and nonresponders originating from study BREEZE-AD7. J Eur Acad Dermatol Venereol. 2023 (Dec 14, 2022). Doi: 10.1111/jdv.18816